2025年5月21日 周三
Home > Archive>Volume 29, Issue 5, 2021 >446-450
PDF HTML XML Export Cite reminder
Update on glucagon-like peptide-1 receptor agonists in metabolic associated fatty liver disease
Author:
Affiliation:

1.Department of Endocrinology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China;2.Department of Endocrinology, the First Affiliated Hospital of Tsinghua University, Beijing 100016, China;3.Department of Physiology and Pathophysiology, School of Basic Medical Sciences & Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Capital Medical University, Beijing 100069, China)

Clc Number:

R589.2

  • Article
    • | |
  • Metrics
    • |
  • Reference
    • |
  • Related
    • |
  • Cited by
    • | |
  • Comments
    Abstract:

    Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive lipid deposition within the liver parenchyma, and is usually accompanied with obesity, insulin resistance, type 2 diabetes (T2DM), insulin resistance, metabolic syndrome. Recently, NAFLD has been officially renamed metabolic associated fatty liver disease (MAFLD).Nonalcoholic steatohepatitis (NASH) is a progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma.Currently there are no approved drugs available for NAFLD/NASH treatment. Glucagon-like peptide-1 (GLP-1) receptor agonist not only reverses the progression of NAFLD indirectly through an incretin effect that improves key metabolic parameters involved in NAFLD, but also has a direct effect on lipid metabolism, inflammation and oxidative stress of hepatocytes. Herein, this study reviews the effects and potential mechanisms of GLP-1 receptor agonists on nonalcoholic fatty liver disease.

    Reference
    Related
    Cited by
Get Citation

LI Na, LIU Jia, WANG Guang, XIE Guomin, QU Aijuan, LI Hongmei. Update on glucagon-like peptide-1 receptor agonists in metabolic associated fatty liver disease[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(5):446-450.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:April 01,2020
  • Revised:June 08,2020
  • Online: April 23,2021
Article QR Code

You are the 47163 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025